Additionally, the exploration of radiolabeled PSMA ligands holds promise for the development of targeted radiotherapy, potentially improving outcomes by selectively delivering radiation to PSMA-expressing cancer cells and minimizing damage to surrounding healthy tissues. The gene discussed is FOLH1; the disease is cancer.